Molecular imaging as biomarker for treatment response and outcome in breast cancer.

ABSTRACT: Molecular imaging, such as positron emission tomography (PET), is increasingly used as biomarker to predict and assess treatment response in breast cancer. The number of biomarkers is expanding with specific tracers for tumour characteristics throughout the body and this information can be used to aid the decision-making process. These measurements include metabolic activity using [¹⁸F]fluorodeoxyglucose PET ([¹⁸F]FDG-PET), oestrogen receptor (ER) expression using 16α-[¹⁸F]Fluoro-17β-oestradiol ([¹⁸F]FES)-PET and human epidermal growth factor receptor 2 (HER2) expression using PET with radiolabelled trastuzumab (HER2-PET). In early breast cancer, baseline [¹⁸F]FDG-PET is frequently used for staging, but limited subtype-specific data re

SUBMITTER: van Geel JJL 

PROVIDER: S-EPMC10201167 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature